Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

1.5K
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
1.5K
Receptor-mediated Endocytosis01:38

Receptor-mediated Endocytosis

111.6K
Overview
111.6K
Types of Hormones02:13

Types of Hormones

84.6K
Hormones can be classified into three main types based on their chemical structures: steroids, peptides, and amines. Their actions are mediated by the specific receptors they bind to on target cells.
84.6K
What are Lipids?01:38

What are Lipids?

221.4K
Overview
221.4K
Dietary Connections01:23

Dietary Connections

62.3K
In biological systems, most metabolic pathways are interconnected. The cellular respiration processes that convert glucose to ATP—such as glycolysis, pyruvate oxidation, and the citric acid cycle—tie into those that break down other organic compounds. As a result, various foods—from apples to cheese to guacamole—end up as ATP. In addition to carbohydrates, food also contains proteins and lipids—such as cholesterol and fats. All of these organic compounds are used...
62.3K
Accessory Organs01:31

Accessory Organs

74.6K
Accessory organs are those that participate in the digestion of food but do not come into direct contact with it like the mouth, stomach, or intestine do. Accessory organs secrete enzymes into the digestive tract to facilitate the breakdown of food.
74.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Angiopoietin-like protein 3 complete and partial deficiency markedly accelerates apolipoprotein B48 and B100 metabolism in triglyceride-rich lipoproteins in humans.

Journal of internal medicine·2026
Same author

Clinical relevance of per-particle atherogenicity of triglyceride-rich lipoproteins, Lp(a) and LDL for cardiovascular risk.

Pharmacology & therapeutics·2026
Same author

Apolipoprotein C-III: Risk-factor, Regulator of Triglyceride-rich Lipoprotein Metabolism and Therapeutic Target.

Current atherosclerosis reports·2026
Same author

Risk-weighted apoB: a novel summary metric outperforming traditional lipid biomarkers in predicting coronary heart disease.

European heart journal·2026
Same author

Triglyceride-rich lipoproteins, remnants and atherosclerotic cardiovascular disease: What we know and what we need to know.

Atherosclerosis·2025
Same author

Editorial: The Brussels International Declaration on Lp(a) Testing And Management-A call to action.

Atherosclerosis·2025

Related Experiment Video

Updated: Feb 15, 2026

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.2K

LDL cholesterol: How low to go?

Chris J Packard1

  • 1Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow G12 8QQ, Scotland, UK.

Trends in Cardiovascular Medicine
|January 17, 2018
PubMed
Summary
This summary is machine-generated.

Lowering LDL cholesterol is crucial for preventing cardiovascular disease, with no safe lower limit. Prioritize high-risk patients for potent therapies like PCSK9 inhibitors to maximize benefits.

Keywords:
PCSK9 inhibitorcardiovascular diseaseclinical trialpreventionstatin

More Related Videos

Cholesterol Efflux Assay
07:54

Cholesterol Efflux Assay

Published on: March 6, 2012

30.7K
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.1K

Related Experiment Videos

Last Updated: Feb 15, 2026

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.2K
Cholesterol Efflux Assay
07:54

Cholesterol Efflux Assay

Published on: March 6, 2012

30.7K
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.1K

Area of Science:

  • Cardiology
  • Lipid Metabolism
  • Preventive Medicine

Background:

  • The causal link between LDL cholesterol and atherosclerotic cardiovascular disease (ASCVD) is well-established, extending to very low levels.
  • Current guidelines face challenges in setting LDL cholesterol targets due to the continuous risk association.

Purpose of the Study:

  • To address the clinical dilemma of LDL cholesterol lowering in the era of potent therapies.
  • To guide the selective use of advanced lipid-lowering treatments based on risk stratification.

Main Methods:

  • Review of epidemiological data and large-scale outcome trials.
  • Analysis of the implications of potent LDL-lowering agents, such as PCSK9 inhibitors.
  • Application of risk-benefit principles for combination lipid-lowering therapy.

Main Results:

  • Evidence supports a continuous, causal relationship between LDL cholesterol and ASCVD risk, without a 'safe' lower threshold.
  • Proprotein convertase/subtilisin kexin type 9 (PCSK9) inhibitors enable profound LDL cholesterol reduction.
  • Health economic considerations necessitate selective application of these advanced therapies.

Conclusions:

  • There is no scientific basis for an LDL cholesterol 'floor' or target.
  • Prioritizing patients with established cardiovascular disease (CVD) and elevated LDL cholesterol on statins maximizes absolute risk reduction.
  • Selective use of potent lipid-lowering therapies, guided by risk, is essential for optimizing outcomes and resource allocation.